Trade Gilead ^GILD

Sacituzumab Govitecan Does Not Significantly Improve OS in Pretreated Urothelial Carcinoma

Assembly Bio Receives Total $30.1 Mln As Equity Investment, Funding From Gilead, Stock Up

Assembly Biosciences Shares Rise 19% After Gilead Investment, Funding | Morningstar

Gilead Sciences acquires $1.83 million in Xilio Therapeutics stock By Investing.com

Assembly Biosciences Announces $30.1 Million Equity Investment and Accelerated Funding from Gilead to Advance Clinical Development Programs | The Manila Times

Xilio Therapeutics Enters into Additional Private Placement with Gilead; Issues Securities at $25 Million Aggregate Investment

Announces preliminary Phase 1 data for XTX301, a tumor-activ

Assembly Biosciences Announces $30.1 Million Equity Investment and Accelerated Funding from Gilead to Advance Clinical Development Programs By Investing.com

USFDA gives nod to Lupin’s generic formulation to treat HIV infection

Gilead Sciences (GILD) Gains As Market Dips: What You Should Know - December 19, 2024 - Zacks.com

Lupin Limited: Lupin’s HIV tablets get FDA nod, Pharma News, ETPharma

Andrew D. Dickinson Sells 8,500 Shares of Gilead Sciences, Inc. (NASDAQ:GILD) Stock

Biotech Stock Roundup: Updates From GILD, REGN, GSK, ANAB Down on Study Data, EWTX Gains - December 18, 2024 - Zacks.com

5 High Earnings Yield Value Picks to Buy for 2025 - December 18, 2024 - Zacks.com

GILD's Trodelvy Gets Second Breakthrough Therapy Tag for Lung Cancer - December 18, 2024 - Zacks.com

Gilead and Terray Therapeutics collaborate on drug discovery | BioWorld

New HIV prevention drug could reach poorest countries by 2025, says health official | The Star

Gilead Sciences CFO sells $781,660 in stock By Investing.com

FDA grants breakthrough status to Gilead's lung cancer drug By Investing.com

Gilead Sciences, Terray Therapeutics Set AI-Powered Research Collaboration | Morningstar

FDA Grants Breakthrough Therapy Status To Gilead's Trodelvy For Treatment Of Small Cell Lung Cancer

Gilead Inks Strategic Collaboration With Terray Therapeutics To Develop Small Molecule Therapies

B. Riley Wealth Advisors Inc. Sells 15,668 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

New HIV prevention drug could reach poorest countries by 2025, says health official By Reuters

Bernstein remains bullish on Gilead stock, sees leadership strengthening future growth By Investing.com

Gilead partners with Terray for AI-driven drug discovery By Investing.com

Gilead Sciences, Inc. (NASDAQ:GILD) Sees Large Increase in Short Interest

Gilead (GILD) Upgraded to Buy: Here's Why - December 16, 2024 - Zacks.com

GILD Obtains Positive CHMP Opinion for Liver Disease Drug - December 16, 2024 - Zacks.com

Roche Gets Approval for Vabysmo PFS in EU for Three Retinal Diseases - December 16, 2024 - Zacks.com

Gilead Sciences' SWOT analysis: lenacapavir success fuels HIV stock growth By Investing.com

Gilead Sciences, Inc. (NASDAQ:GILD) Shares Purchased by Franklin Resources Inc.

Gilead Sciences, Inc. (NASDAQ:GILD) Shares Acquired by Synovus Financial Corp

Wilmington Savings Fund Society FSB Has $1.56 Million Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Gilead Sciences, Inc. (NASDAQ:GILD) Receives Average Recommendation of "Moderate Buy" from Brokerages

DGS Capital Management LLC Sells 1,492 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

DGS Capital Management LLC Has $300,000 Position in Gilead Sciences, Inc. (NASDAQ:GILD)

50,000 Shares in Gilead Sciences, Inc. (NASDAQ:GILD) Bought by Exome Asset Management LLC

2,495 Shares in Gilead Sciences, Inc. (NASDAQ:GILD) Purchased by Pine Valley Investments Ltd Liability Co

2,883 Shares in Gilead Sciences, Inc. (NASDAQ:GILD) Acquired by Brass Tax Wealth Management Inc.

Retirement Systems of Alabama Cuts Stake in Gilead Sciences, Inc. (NASDAQ:GILD)

Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by American Trust

Tri Ri Asset Management Corp Buys Shares of 40,314 Gilead Sciences, Inc. (NASDAQ:GILD)

Gilead Sciences, Inc. (NASDAQ:GILD) Shares Purchased by Tidal Investments LLC

Gilead Gets Key European Backing for Liver-Disease Treatment | Morningstar

Gilead Sciences, Inc. (NASDAQ:GILD) Stock Position Lifted by Sanctuary Advisors LLC

Gilead Sciences Says Seladelpar Gets Positive CHMP Opinion For Primary Biliary Cholangitis

Leerink Partnrs Lifts Earnings Estimates for Gilead Sciences

Gilead’s Seladelpar Receives Positive CHMP Opinion for Primary Biliary Cholangitis | Morningstar

Gilead Sciences, Inc. (NASDAQ:GILD) Position Trimmed by TCW Group Inc.

Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Teachers Retirement System of The State of Kentucky

XTX Topco Ltd Takes Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Gilead Sciences: Gilead appoints Sanofi official Dietmar Berger as next chief medical officer, ETPharma

Seladelpar wins CHMP endorsement for rare liver disease By Investing.com

Gilead Sciences (GILD) Stock Moves -0.57%: What You Should Know - December 13, 2024 - Zacks.com

Stock Traders Purchase Large Volume of Call Options on Gilead Sciences (NASDAQ:GILD)

SkyView Investment Advisors LLC Purchases 435 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Blankinship & Foster LLC Takes $1.01 Million Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Gilead appoints Sanofi official Dietmar Berger as next chief medical officer By Reuters

Arvest Bank Trust Division Takes Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Te Ahumairangi Investment Management Ltd Sells 9,587 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Zacks Research Forecasts Higher Earnings for Gilead Sciences

Tri Ri Asset Management Corp Takes Position in Gilead Sciences, Inc. (NASDAQ:GILD)

TD Private Client Wealth LLC Increases Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

Toronto Dominion Bank Trims Stake in Gilead Sciences, Inc. (NASDAQ:GILD)

Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It - December 12, 2024 - Zacks.com

Is Gilead Sciences (GILD) Stock Undervalued Right Now? - December 12, 2024 - Zacks.com

CADL Stock Soars as Phase III Prostate Cancer Study Meets Primary Goal - December 12, 2024 - Zacks.com

Gilead Sciences’ (GILD) “Neutral” Rating Reiterated at Cantor Fitzgerald

Macy's gives update on employee who hid $151M

Gilead Sciences, Inc. (GILD) To Go Ex-Dividend on December 13th

Gilead stock outlook hinges on Lenacapavir's PrEP launch and untapped patient expansion, says DB By Investing.com

TT International Asset Management LTD Invests $1.26 Million in Gilead Sciences, Inc. (NASDAQ:GILD)

LRI Investments LLC Boosts Position in Gilead Sciences, Inc. (NASDAQ:GILD)

M&T Bank Corp Has $16.18 Million Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

This pharma stock could easily gain 20% next year, Jefferies says By Investing.com

CRDF Stock Soars on Robust Efficacy Data From Colorectal Cancer Study - December 11, 2024 - Zacks.com

QURE Soars on FDA Alignment for Speedy Approval of Huntington's Drug - December 11, 2024 - Zacks.com

Vestcor Inc Reduces Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

Oppenheimer Forecasts Strong Price Appreciation for Gilead Sciences (NASDAQ:GILD) Stock

Gilead Sciences (NASDAQ:GILD) Given "Buy" Rating at Bank of America

15,203 Shares in Gilead Sciences, Inc. (NASDAQ:GILD) Purchased by Brophy Wealth Management LLC

Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Vestcor Inc

Groupama Asset Managment Acquires 24,956 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Gilead Sciences, Inc. (NASDAQ:GILD) Shares Bought by MML Investors Services LLC

The Zacks Analyst Blog Highlights Eli Lilly, AbbVie, Gilead Sciences, Air T and Fossil Group

KOD Stock Up as Jefferies Upgrades Rating on Huge Pipeline Potential - December 10, 2024 - Zacks.com

Longest Follow-Up Data Reported for Kite’s Tecartus® CAR T-Cell Therapy at ASH 2024 Reinforce Durable Efficacy and Survival Benefits

Gilead Sciences : Longest Follow-Up Data Reported for Kite’s Tecartus CAR T-Cell Therapy at ASH 2024 Reinforce Durable Efficacy and Survival Benefits By Investing.com

Abel Hall LLC Cuts Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Nomura Asset Management Co. Ltd. Sells 97,655 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Top Stock Reports for Eli Lilly, AbbVie & Gilead Sciences

FDA Accepts GSK's Filing for Expanded Use of Nucala in COPD - December 9, 2024 - Zacks.com

Weiss Asset Management LP Invests $1.68 Million in Gilead Sciences, Inc. (NASDAQ:GILD)

Analyst revises Amazon stock forecast following major 'moonshot' initiative

Stock market today: 3 bullish stocks that J.P. Morgan Just Upgraded

Bitcoin news today: Jerome Powell Says Fed Won’t Hold Bitcoin

Gold performance and prediction: how high could gold price go?

Week ahead: Last full week of 2024 in the Financial Markets

Stock market today: Nasdaq Hits Record Highs as Tesla Achieves New Peaks

Dow Jones tumbles 1,100 points: why did the stock market go down today?

Super Micro Shares Drop 8% Following Nasdaq 100 Removal